Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo (irmsrct)
Multiple sclerosis: KIR4.1 as an autoantigen in MS-new questions raised.
MRI Study: Objective Olfactory Function and CNS Pathologies in Patients with Multiple Sclerosis.
Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10.
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.
[Affective and psychotic disorders in multiple sclerosis].
Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis.
Vestibular-evoked myogenic potentials, clinical evaluation, and imaging findings in multiple sclerosis.
Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.
The Interdependent, Overlapping, and Differential Roles of Type I and II IFNs in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Efficient in vivo depletion of CD8(+) T lymphocytes in common marmosets by novel CD8 monoclonal antibody administration.
Biomechanical disorders of foot in multiple sclerosis.
The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis.
MicroRNA-21 with therapeutic potential in autoimmune diseases.
The effects of exercise training on fitness, mobility, fatigue, and health related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development.
The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease.
Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.
Relationship between contrast sensitivity test and disease severity in multiple sclerosis patients.
Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury.
Dissection of a Complex Disease Susceptibility Region Using a Bayesian Stochastic Search Approach to Fine Mapping.
Sexual dysfunction in multiple sclerosis: A 6-year follow-up study.
MMP-9 in Translation: From Molecule to Brain Physiology, Pathology and Therapy.
Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature.
PDE4B as a microglia target to reduce neuroinflammation.
Relevance of brain lesion location to cognition in relapsing multiple sclerosis.
Pages
« first
‹ previous
…
328
329
330
331
332
333
334
335
336
…
next ›
last »